Relief Reports U.S. Collaboration Partner has Announced Favorable New Safety Report for Aviptadil in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19

Rhea-AI Summary

Relief Therapeutics (OTCQB: RLFTF) announced a positive safety update regarding aviptadil from its U.S. partner, NRx Pharmaceuticals, as part of the NIH-sponsored ACTIV-3b study. The Independent Data Safety Monitoring Board analyzed over 300 patients and found no new safety concerns, recommending continued enrollment to reach 640 patients. Relief's lead drug, RLF-100(TM), aims to treat respiratory deficiency due to COVID-19. The company also broadened its portfolio through recent acquisitions and collaborations.

Positive

• Favorable safety update for aviptadil from NRx, with no new safety concerns found.
• Independent Data Safety Monitoring Board recommends continued enrollment in the study.
• Diversified pipeline through acquisitions and collaborations to strengthen market position.

Negative

• None.

GENEVA, SWITZERLAND / ACCESSWIRE / November 3, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent company of its U.S. collaboration partner, NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (" NRx "), has issued a press release announcing a new safety update on aviptadil, which is being tested in the ACTIV-3b Critical Care Phase 3 study sponsored by the National Institutes of Health. According to the press release, in its third scheduled analysis, the study's Independent Data Safety Monitoring Board found no new safety concerns after reviewing a total of more than 300 patients and recommended continued enrollment to target 640 patients. The related NRx press release can be accessed through the following link.

ABOUT RELIEF

Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale. Relief's lead drug candidate, RLF-100(TM) (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory deficiency due to COVID-19. As part of its pipeline diversification strategy, in March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle Disorders and Maple Syrup Urine Disease. In addition, Relief's recently completed acquisitions of APR Applied Pharma Research SA and AdVita Lifescience GmbH, bring to Relief a diverse pipeline of marketed and development-stage programs.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF. For more information, visit www.relieftherapeutics.com . Follow us on LinkedIn.

CONTACT:
RELIEF THERAPEUTICS Holding SA
Jack Weinstein
Chief Financial Officer and Treasurer
contact@relieftherapeutics.com

FOR MEDIA/INVESTOR INQUIRIES:
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding SA. Such statements involve certain known and unknown risks, uncertainties and other factors, including (i) whether aviptadil will ever be approved in the U.S., the U.K., or the E.U. for the treatment of respiratory failure in patients with COVID-19, and (ii) those risks discussed in RELIEF THERAPEUTICS Holding SA's press releases and filings with the SIX, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

SOURCE: Relief Therapeutics Holdings AG

View source version on accesswire.com:
https://www.accesswire.com/670946/Relief-Reports-US-Collaboration-Partner-has-Announced-Favorable-New-Safety-Report-for-Aviptadil-in-NIH-Sponsored-ACTIV-3b-Critical-Care-Study-in-Patients-with-Life-Threatening-COVID-19

FAQ

What is the latest news about Relief Therapeutics and aviptadil?

Relief Therapeutics reported a positive safety update on aviptadil from its partner NRx Pharmaceuticals, with no new safety concerns found in the ACTIV-3b study.

What does the safety update for aviptadil mean for Relief Therapeutics?

The update indicates that ongoing studies can continue, which may accelerate potential approval for aviptadil in treating respiratory issues related to COVID-19.

What is the current status of aviptadil in clinical trials?

Aviptadil is undergoing a Phase 3 study, with 640 patients targeted for enrollment, following a report of no new safety concerns.

What is the significance of the ACTIV-3b study for Relief Therapeutics?

The ACTIV-3b study, sponsored by the NIH, is crucial for evaluating aviptadil's efficacy and safety in critical care settings for COVID-19.

How does Relief Therapeutics plan to expand its drug pipeline?

Relief has diversified its pipeline through recent acquisitions and collaborations, enhancing its development capabilities for various therapeutic areas.